hit counter
Bellicum Pharmaceuticals, Inc. (BLCM) Stock News Sentiment & Price - Sentifly
BLCM - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Bellicum Pharmaceuticals, Inc. (BLCM)

USA
Biotechnology
NASDAQ
BLCM Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BLCM Latest news
GlobeNewsWire
Neutral
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-03 07:30

HOUSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference (Virtual). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 13, 2021 and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.

Benzinga
Positive
Why Is Bellicum Stock Moving Higher On Wednesday?
2021-09-01 09:01

Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and The University of Texas MD Anderson Cancer Center have announced a global option and license agreement for Bellicum's CaspaCIDe (inducible caspase-9, or iC9) safety switch, and rimiducid, an agent used to activate the safety switch.  Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.

Pulse2
Positive
BLCM Stock: Over 12% Increase Pre-Market Explanation
2021-09-01 08:22

The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) increased over 12% pre-market. This is why it happened.

GlobeNewsWire
Neutral
Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
2021-09-01 07:30

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum's CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Under this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.

GlobeNewsWire
Neutral
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-07-26 17:25

HOUSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grant with an effective date of July 26, 2021. The stock options were granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

GlobeNewsWire
Neutral
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
2021-06-28 07:30

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) and Massachusetts General Hospital (Mass General) covering certain intellectual property and technology rights regarding the company's CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid. CaspaCIDe may facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed, in the pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next generation higher potency cell therapy constructs.

GlobeNewsWire
Neutral
Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
2021-05-17 07:30

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update.

Seeking Alpha
Neutral
Bellicum Pharmaceuticals: Narrowing The Thesis And Simplifying The Investment
2021-05-13 11:48

Over the past couple of years, Bellicum Pharmaceuticals has made several changes that have streamlined their pipeline and their OpEx. Consequently, I have had to adjust my thesis and expectations. Bellicum was only a few quarters away from being a commercial company and collecting revenue. Now, the company is back to proof-of-concept and Phase I trials.

Seeking Alpha
Neutral
Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript
2021-03-30 22:23

Bellicum Pharmaceuticals, Inc. (BLCM) CEO Richard Fair on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
2021-03-30 16:05

Enrolled first patient in Phase 1/2 clinical trial for BPX-603 in solid tumors that express HER2

Loading more news...